Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Dainippon Will Buy Boston Biomedical
by Michael McCoy
March 5, 2012
| A version of this story appeared in
Volume 90, Issue 10
Dainippon Sumitomo Pharma has agreed to acquire Boston Biomedical Inc. for $200 million. Based in Norwood, Mass., BBI is developing two small-molecule drugs that work by targeting cancer stem cells. One, BBI608, is being prepared for a Phase III clinical trial as a colorectal cancer treatment and is in Phase Ib and II trials for various solid tumors. The other, BBI503, is in Phase I trials for solid tumors. Under the deal, BBI’s six shareholders also can get up to $540 million in developmental milestone payments. Dainippon Sumitomo licensed Japanese rights to BBI608 in March 2011.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter